Dive into the Soleno Therapeutics $SLNO controversy as we break down a securities class action tied to drug safety, rare disease treatments, and alleged misleading statements around Vykat XR. This episode is for investors, traders, and anyone following biotech stocks, FDA approvals, and market risk. Expect deep dives, real case analysis, and insights into safety concerns, patient outcomes, and stock declines.

Visit ZLK.com for more info.

Add our WhatsApp Channel

We’re not lawyers or accountants, so don’t take this as legal or financial advice.